Navigation Links
Bioniche Pharma and Academic Pharmaceuticals, Inc. Announce the Introduction of Sotalol Hydrochloride Injection
Date:11/16/2009

LAKE FOREST, Ill. and LAKE BLUFF, Ill., Nov. 16 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Academic Pharmaceuticals, Inc (API), a research and development company specializing in cardiovascular products, announced today that Sotalol Hydrochloride (HCl) Injection for intravenous use is now available. Sotalol Hydrochloride tablets are currently available under the brand name Betapace®.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)

Bioniche Pharma and API entered into an agreement whereby API developed and secured the FDA approval of Sotalol HCl Injection and Bioniche Pharma maintains the exclusive rights to manufacture, market, and distribute the product in the United States.

"Bioniche Pharma is very pleased to launch Sotalol HCl Injection," said George Zorich, President, US Operations for Bioniche Pharma. "We partnered with API due to their knowledge of anti-arrhythmic treatment options and patient needs. This product expands Bioniche Pharma's growing portfolio of branded products and demonstrates our commitment to aggressively expanding our product line."

Sotalol HCl Injection is currently available and Bioniche Pharma will be attending the November

American Heart Association meeting in Orlando, Florida as part of their introduction of the product.

Sotalol HCl Injection has a black box warning relating to life threatening proarrhythmia. Please refer to

the Bioniche Pharma website for the complete prescribing information, including the boxed warning.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology, and dermatology. An internal development pipeline and an aggressive acquisition strategy for products fuel the company's growth. RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois, acquired Bioniche Pharma in February 2006. More information about Bioniche Pharma can be found at www.bionichepharma.com.

About Academic Pharmaceuticals, Inc.:

Academic Pharmaceuticals Inc is a Research and Development company specializing in Cardiovascular products. The company specializes in developing anti-arrhythmic parenteral compounds and other cardiovascular drugs that are needed by practicing cardiologists or emergency room physicians. Many of the products in development are orphan drugs that serve specialized populations. The company's expertise is in solubilization of insoluble compounds and designing expedited clinical development and regulatory review programs. The company offices are in Lake Bluff, Illinois.

Betapace® is a registered trademark of Bayer Schering Pharma.

SOURCE Bioniche Pharma


'/>"/>
SOURCE Bioniche Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
2. Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... N.J. , Dec. 5, 2016  Daiichi ... preliminary safety and efficacy data from a phase ... MDM2 inhibitor, suggesting that DS-3032 may be a ... myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). ... the phase 1 study of DS-3032 were presented in ...
(Date:12/5/2016)... -- BD (Becton, Dickinson and Company) (NYSE: BDX ... an enhanced technology platform designed with the ability to ... Pyxis™ and Alaris™ systems, at this year,s American ... being held in Las Vegas ... that approximately 68 percent of medication errors occur during ...
(Date:12/5/2016)... , Dec. 5, 2016 Eisai Inc. ... at the 2016 Annual Meeting of the American Epilepsy ... CIII, is indicated as an adjunctive therapy for the ... secondarily generalized seizures and primary generalized tonic-clonic seizures (PGTC) ... age and older. Please see Important Safety Information for ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... It can be argued that people these days ... members as they do for their human friends and family. As pets have ... highest quality and most innovative pet products has also increased. , For ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Behavioral Health Center ... recognizing the organization as a top behavioral service provider in the country. The ... quality, staff satisfaction and qualifications, and consumer satisfaction. These areas are measured via ...
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway Analytical, one of ... particle counting and sizing services for USP 788 and 789 particulate standards compliance. ... as a response to the needs of pharmaceutical and medical device manufacturers, who ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement has a ... world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms every day ...
(Date:12/6/2016)... Vancouver, B.C., Canada (PRWEB) , ... December 06, ... ... Consultants (STC) announce the availability of the newly updated International Audit Protocol Consortium ... world use IAPC EHS audit protocols to understand the scope of their EHS ...
Breaking Medicine News(10 mins):